Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Objectives:
- To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with
fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary
serous carcinoma.
- To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in
this cohort of patients.
- To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage
IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either
c-Kit, PDGFR or abl.